{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:02:09Z","timestamp":1782889329121,"version":"3.54.5"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We present the case of a 58-year-old man with metastatic medullary thyroid carcinoma refractory to conventional therapies, including peptide receptor radionuclide therapy. Despite multiple interventions, serum calcitonin and carcinoembryonic antigen levels continued to rise. Subsequent evaluation with <jats:sup>99m<\/jats:sup>Tc-FAPI-46 revealed remarkable uptake in metastatic lesions, suggesting a potential role for FAPI-labeled radioisotopes in the management of medullary thyroid carcinoma. This case underscores the emerging utility of FAPI-targeted radiotracers in oncologic nuclear medicine and highlights the need for further research in this promising area.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005605","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T06:00:48Z","timestamp":1735624848000},"page":"e209-e210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Application of 99mTc-FAPI-46 Imaging in a Patient With Medullary Thyroid Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2087-2169","authenticated-orcid":false,"given":"Nasrin","family":"Raeisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Barashki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Nateghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"bib1-20250303","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1021\/acs.jmedchem.4c00031","article-title":"Synthesis and preclinical evaluation of novel 99m Tc-labeled FAPI-46 derivatives with significant tumor uptake and improved tumor-to-nontarget ratios","volume":"67","year":"2024","journal-title":"J Med Chem"},{"key":"bib2-20250303","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of 99mTc-labeled FAPI tracers for SPECT imaging and 188Re therapy","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib3-20250303","doi-asserted-by":"crossref","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","article-title":"Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review","volume":"14","year":"2024","journal-title":"Front Oncol"},{"key":"bib4-20250303","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","year":"2018","journal-title":"Cancer Cell"},{"key":"bib5-20250303","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ijgc-2020-001822","article-title":"Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy","volume":"31","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"bib6-20250303","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/RLU.0000000000004532","article-title":"18F-FDG and 68Ga-FAPI-04 PET\/CT in evaluating clear-cell endometrial cancer","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib7-20250303","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High diagnostic value of 18 F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib8-20250303","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in radioligand theranostics in oncology","volume":"28","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"bib9-20250303","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nucmedbio.2020.06.005","article-title":"The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy","volume":"92","year":"2021","journal-title":"Nucl Med Biol"},{"key":"bib11-20250303","article-title":"Cancer Theranostics: Pharmaceutical View","year":"2024","journal-title":"Pharm Sci Smart Drug Deliv Syst"},{"key":"bib13-20250303","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.3390\/molecules27206790","article-title":"PET oncological radiopharmaceuticals: current status and perspectives","volume":"27","year":"2022","journal-title":"Molecules"},{"key":"bib14-20250303","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1097\/RLU.0000000000005469","article-title":"Variable tracer avidity and interlesional heterogeneity on 18F-FDG, 68Ga-DOTATATE, and 68Ga-DOTA-FAPi-04 PET\/CT imaging in a single individual patient with progressive metastatic medullary thyroid carcinoma","volume":"49","year":"2024","journal-title":"Clin Nucl Med"},{"key":"bib15-20250303","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/RLU.0000000000005259","article-title":"False-negative 68Ga-FAPI PET\/CT in pediatric thyroid medullary carcinoma seen with 68Ga-DOTATOC PET\/CT and 18F-FDG PET\/CT","volume":"49","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:00:17Z","timestamp":1741024817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005605"}},"subtitle":["Navigating the Landscape of Novel Radiotracers"],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005605","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}